help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Widmaier, E. P.
Right arrow Articles by Vale, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Widmaier, E. P.
Right arrow Articles by Vale, W.

Endocrinology, Vol 124, 583-590, Copyright © 1989 by Endocrine Society


ARTICLES

Secretion of corticotropin-releasing factor from cultured rat hypothalamic cells: effects of catecholamines

EP Widmaier, AT Lim and W Vale
Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California 92037.

An understanding of the regulation of CRF secretion in rats is currently incomplete, in part due to the lack of sensitive in vitro models available for studying this neuropeptide. In particular, the effects of catecholamines on CRF secretion, and the receptor subtypes mediating these actions have long been the subject of much debate. A cultured cell model has been adapted for studying secretory responses of hypothalamic cells of 1-week-old rats. Between 7-16 days in monolayer culture the cells secreted detectable levels of immunoreactive CRF, and this release was paralleled by the appearance of punctate bead-like regions of immunoreactivity along fine cellular processes. CRF secretion was increased up to 4-fold by norepinephrine (EC50, approximately 0.5 microM). The increase in CRF secretion produced by norepinephrine was blocked by the beta-receptor antagonist propranolol, but not by the alpha-antagonist prazosin. Moreover, the beta-receptor agonist isoproterenol significantly elevated CRF secretion, whereas the alpha-agonist phenylephrine was without effect, except at high concentrations. Addition of phenylephrine, however, potentiated the effect of isoproterenol, but this response was still significantly less than that produced by norepinephrine. Forskolin (EC50, approximately 0.7 microM) and the active phorbol ester 12-O- tetradecanoyl-phorbol-13-acetate (EC50, approximately 40 nM) also increased CRF secretion by 3- to 4-fold. Inactive phorbol derivatives had no effect on CRF release from these cultures. The results indicate that cultured neonatal rat hypothalamic cells are a powerful model for the study of CRF release in vitro, and that norepinephrine acts directly at the isolated cell level to stimulate secretion of this peptide, primarily by activating beta-adrenoceptors. The results also suggest that at least two functional second messenger systems (adenylate cyclase and protein kinase-C) are involved in CRF secretion and are already functional in the neonatal hypothalamus.


This article has been cited by other articles:


Home page
EndocrinologyHome page
S. M. Smith, J. M. Vaughan, C. J. Donaldson, J. Rivier, C. Li, A. Chen, and W. W. Vale
Cocaine- and Amphetamine-Regulated Transcript Activates the Hypothalamic-Pituitary-Adrenal Axis through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism
Endocrinology, November 1, 2004; 145(11): 5202 - 5209.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
F. Leri, J. Flores, D. Rodaros, and J. Stewart
Blockade of Stress-Induced But Not Cocaine-Induced Reinstatement by Infusion of Noradrenergic Antagonists into the Bed Nucleus of the Stria Terminalis or the Central Nucleus of the Amygdala
J. Neurosci., July 1, 2002; 22(13): 5713 - 5718.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Robidoux, L. Simoneau, A. Masse, and J. Lafond
Activation of L-Type Calcium Channels Induces Corticotropin-Releasing Factor Secretion from Human Placental Trophoblasts
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3356 - 3364.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
J. Robidoux, L. Simoneau, S. St-Pierre, A. Masse, and J. Lafond
Characterization of Neuropeptide Y-Mediated Corticotropin-Releasing Factor Synthesis and Release from Human Placental Trophoblasts
Endocrinology, August 1, 2000; 141(8): 2795 - 2804.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. L. Laorden, M. T. Castells, M. D. MartInez, P. J. MartInez, and M. V. Milanes
Activation of c-fos Expression in Hypothalamic Nuclei by {micro}- and {kappa}-Receptor Agonists: Correlation with Catecholaminergic Activity in the Hypothalamic Paraventricular Nucleus
Endocrinology, April 1, 2000; 141(4): 1366 - 1376.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M.V. Milanés, M.L. Laorden, M. Chapleur-Château, and A. Burlet
Alterations in Corticotropin-Releasing Factor and Vasopressin Content in Rat Brain during Morphine Withdrawal: Correlation with Hypothalamic Noradrenergic Activity and Pituitary-Adrenal Response
J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 700 - 706.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
J. W. Kasckow, A. Regmi, P. S. Gill, D. G. Parkes, and T. D. Geracioti
Regulation of Corticotropin-Releasing Factor (CRF) Messenger Ribonucleic Acid and CRF Peptide in the Amygdala: Studies in Primary Amygdalar Cultures
Endocrinology, November 1, 1997; 138(11): 4774 - 4782.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society